SeaStar Medical (ICU) announces the shipment of its QUELIMMUNE device to a prominent academic medical center, representing SeaStar Medical’s fourth commercial customer. QUELIMMUNE is the company’s Selective Cytopheretic Device for treating critically ill children in the intensive care unit with acute kidney injury and sepsis.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar Medical activates 14th hospital for adult AKI trial
- SeaStar Medical sees TAM for SCD in five clinical indications of $25B-$35B
- SeaStar Medical announces activation of Sentara Norfolk General as active site
- SeaStar announces two advisory firms recommended vote favor of proposals
- SeaStar Medical reaches milestone of 100th QUELIMMUNE commercial device